- Co announces organizational changes designed to accelerate its transformation into a leading rare disease therapeutics company. Co is consolidating its development and scientific functions under Adrian Quartel, M.D., FFPM, Chief Medical Officer. Adrian will be responsible for clinical development, quality assurance, and regulatory and scientific affairs. As part of these changes, Christal M.M. Mickle, Chief Development Officer, and Sven Guenther, Ph.D., Chief Scientific Officer, are departing Zevra effective December 6, 2024, and December 23, 2024, respectively.
- Co has also eliminated positions in chemistry, manufacturing and controls and Clinical Development, consistent with the change in portfolio priorities.
Trade with Eva: Analytics in action >>
Monday, December 9, 2024
===Zevra Therapeutics (ZVRA) announces organizational changes
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment